The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2193-6528
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study ; volume:12 ; number:1 ; day:16 ; month:12 ; year:2022 ; pages:561-575 ; date:2.2023
Ophthalmology and therapy ; 12, Heft 1 (16.12.2022), 561-575, 2.2023

Creator
Talks, S. James
Daien, Vincent
Mitchell, Paul
Aslam, Tariq
Barratt, Jane
Biberger, Anna
Lamoureux, Ecosse L.
Hirst, Ceri
Sylvanowicz, Michelle
Finger, Robert P.
Contributor
SpringerLink (Online service)

DOI
10.1007/s40123-022-00631-7
URN
urn:nbn:de:101:1-2023032021110118838866
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Talks, S. James
  • Daien, Vincent
  • Mitchell, Paul
  • Aslam, Tariq
  • Barratt, Jane
  • Biberger, Anna
  • Lamoureux, Ecosse L.
  • Hirst, Ceri
  • Sylvanowicz, Michelle
  • Finger, Robert P.
  • SpringerLink (Online service)

Other Objects (12)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Near-infrared reflectance imaging of neovascular age-related macular degeneration

Near-infrared reflectance imaging of neovascular age-related macular degeneration

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration

Efficacy and safety of abicipar in neovascular age-related macular degeneration

Efficacy and safety of abicipar in neovascular age-related macular degeneration

Vision protection therapy for prevention of neovascular age-related macular degeneration

Vision protection therapy for prevention of neovascular age-related macular degeneration

Treatment of age-related neovascular macular degeneration: the patient’s perspective

Treatment of age-related neovascular macular degeneration: the patient’s perspective

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes

Influence of new societal factors on neovascular age-related macular degeneration outcomes

Influence of new societal factors on neovascular age-related macular degeneration outcomes

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Sub-retinal pigment epithelium tubules in non-neovascular age-related macular degeneration

Sub-retinal pigment epithelium tubules in non-neovascular age-related macular degeneration

Characterization of two-pore channel 2 in neovascular age-related macular degeneration

Characterization of two-pore channel 2 in neovascular age-related macular degeneration

Related objects